Redeye retains its positive view of Lagercrantz after a Q4 report that aligned with our projections.
Underliggande tillväxt trots svagare kvartal Det första kvartalet var sammantaget svagare än motsva...
Redeye reiterates its fair value range following Dala Energi’s Q1 report that was published last Fri...
Redeye comments on Initiator Pharma’s announcements earlier today regarding its clinical expansion i...
Nettoomsättningen för det första kvartalet uppgick till 8,2 MEURO (10,9), vilket motsvarade en minsk...
Biofrigas Sweden AB (publ) (”Biofrigas” eller ”Bolaget”) är verksamma på den växande marknaden för f...
No real progress in Q1 Market to turn positive in '25e, according to report Turnaround delayed, '25e...
Q1 sales +40% y-o-y, +2% q-o-q, FCF negative Cut '25e-'27e sales by 7% on weaker Q2 outlook Market r...
The MSA (Master Service Agreement) include a first study work order of SEK 4m in sales from late 202...
Angler Gaming plc (”Angler” eller ”Bolaget”) levererade en kv1 2025-rapport under vår förväntan avse...
After the warrant contribution, Ascelia Pharma is well funded for 2025 with some SEK 80m net cash, w...
Soft Q1 earnings driven by gross margin pressure in the US Weaker USD weighs on estimates, given US-...
Redeye comments on Lytix Biopharma’s first quarter review of 2025.
Redeye states Safello's report came in on the weaker side in a quarter with a challenging backdrop.
Portfolio rebalancing and weak market behind PW We lower '25e-'27e EBIT by 31-22% on lower sales We ...
Q1 miss, 2025-27e adj. EBITA cut 4-5% FY guidance kept, we estimate 7% EBITA growth in 2025e Share a...
Sales SEK 54m (ABGSCe 55m), EBIT -4m (ABGSCe -7m) Market conditions remain soft, anticipates weaker ...
Redeye provides a brief summary of Elicera’s Q1'25 report.